{
    "nct_id": "NCT04147247",
    "official_title": "An Open-label, Phase I Trial to Determine the Maximum-tolerated Dose and Investigate Safety, Pharmacokinetics and Efficacy of BI 905681 Administered Intravenously in Patients With Advanced Solid Tumours",
    "inclusion_criteria": "Inclusion criteria:\n\n* Histologically or cytologically confirmed diagnosis of an advanced, unresectable and/or metastatic non-haematologic malignancy. Patient must have measurable or evaluable lesions (according to Response Evaluation Criteria in Solid Tumours (RECIST) v 1.1).\n* Patient who has failed conventional treatment or for whom no therapy of proven efficacy exists or who is not eligible for established treatment options.\n* Patients willing to undergo mandatory tumour biopsy at the time points specified in the protocol.\n* Eastern Cooperative Oncology Group (ECOG) Score of 0 or 1 (R01-0787).\n* Adequate organ function defined as all of the following:\n\n  * Absolute neutrophil count (ANC) ≥1.5 x 10^9/L; haemoglobin ≥9.0 g/dL; platelets ≥100 x 10^9/L without the use of haematopoietic growth factors within 4 weeks of start of study medication.\n  * Total bilirubin ≤1.5 x the upper limit of normal (ULN), except for patients with Gilbert's syndrome: total bilirubin ≤3 x ULN or direct bilirubin ≤1.5 x ULN.\n  * Creatinine ≤1.5 x ULN. If creatinine is >1.5 x ULN, patient is eligible if concurrent creatinine clearance ≥50 ml/min (measured or calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula or Japanese version of CKD-EPI formula for Japanese patients).\n  * Aspartate transaminase (AST) and alanine transaminase (ALT) ≤3 x ULN if no demonstrable liver metastases, or otherwise ≤5 x ULN\n  * Alkaline Phosphatase (ALP) <5 x ULN\n* At least 18 years of age at the time of consent or over the legal age of consent in countries where that is greater than 18 years.\n* Signed and dated written informed consent in accordance with International Conference on Harmonisation (ICH) - Good Clinical Practice (GCP) and local legislation prior to admission to the trial\n* Life expectancy ≥3 months at the start of treatment in the opinion of the investigator\n* Further inclusion criteria apply\n\nExclusion criteria:\n\n* Osteoporosis ≥ CTCAE Grade 2\n* Osteoporotic compression fracture within 12 months prior to informed consent which is clinically significant in the opinion of the investigator.\n* Further exclusion criteria apply\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}